84 filings
Page 2 of 5
8-K
ik8wd6eyjkm2i kro5
10 May 23
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
7:14am
DEFA14A
ogmmlu44c72zu 5ji
9 May 23
Additional proxy soliciting materials
8:42am
8-K
chivwmbj 7mwprzn
9 May 23
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
8:15am
ARS
eqglgj81r8jm
27 Apr 23
Annual report to shareholders
7:11am
DEFA14A
p06yotg 70bp23hk5
27 Apr 23
Additional proxy soliciting materials
7:07am
EFFECT
m7ffn4
31 Mar 23
Notice of effectiveness
12:15am
8-K
0cj4hot wlk
30 Mar 23
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
7:10am
CORRESP
wf08mv5xhhx0
28 Mar 23
Correspondence with SEC
12:00am
UPLOAD
ygk9abnd3hd6v
27 Mar 23
Letter from SEC
12:00am
S-8
44ebmo iy
21 Mar 23
Registration of securities for employees
9:17am
S-3
386pux
21 Mar 23
Shelf registration
7:53am
8-K
ixbjh2a7mr
21 Mar 23
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
7:09am
8-K
ulk j3hfl
10 Mar 23
Regulation FD Disclosure
3:34pm
UPLOAD
ptdh 3snph
28 Feb 23
Letter from SEC
12:00am
8-K
k6mqd3r2
10 Feb 23
Departure of Directors or Certain Officers
4:05pm
8-K
o1cin0j077bdlb
9 Jan 23
Regulation FD Disclosure
4:08pm
8-K
ou76 wtgj
15 Dec 22
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
4:15pm